Bart J.M. van Vlijmen

2.9k citations

70 papers · 2.1k indexed · h-index 26

Co-authors: Louis M. Havekes Niels Bovenschen Marten H. Hofker Koen Mertens Theo J.C. van Berkel Lianne S.M. Boesten Mark Kockx Ko Willems van Dijk
Topics: Blood Coagulation and Thrombosis Mechanisms (18 papers)Lipoproteins and Cardiovascular Health (10 papers)Platelet Disorders and Treatments (10 papers)
Cited by: Hematology Internal Medicine Immunology
Journals: Journal of Biological Chemistry Circulation Blood
Partner nations: Netherlands United States France

In The Last Decade

Bart J.M. van Vlijmen

67 papers receiving 2.1k citations

Peers

Countries citing papers authored by Bart J.M. van Vlijmen

Since Specialization

Citations

This map shows the geographic impact of Bart J.M. van Vlijmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart J.M. van Vlijmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart J.M. van Vlijmen more than expected).

Fields of papers citing papers by Bart J.M. van Vlijmen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart J.M. van Vlijmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart J.M. van Vlijmen. The network helps show where Bart J.M. van Vlijmen may publish in the future.

Co-authorship network of co-authors of Bart J.M. van Vlijmen

This figure shows the co-authorship network connecting the top 25 collaborators of Bart J.M. van Vlijmen. A scholar is included among the top collaborators of Bart J.M. van Vlijmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart J.M. van Vlijmen. Bart J.M. van Vlijmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs 2025 ·Blood Advances ·(unknown),(unknown),Richard Dirven,(unknown),Ruben Bierings,Caterina Casari,Robert A. Cordfunke,James E. Dahlman,(unknown),Jan W. Drijfhout,Frank W.G. Leebeek,L. Renee Ruhaak,Elisa Schrader Echeverri,Jan Voorberg,Bart J.M. van Vlijmen,Cécile V. Denis,Jeroen Eikenboom	6
2	Silencing of the von Willebrand factor gene in proatherothrombotic APOE∗3-Leiden.CETP transgenic mice 2025 ·Research and Practice in Thrombosis and Haemostasis ·(unknown),Richard Dirven,Elisa Schrader Echeverri,Anja W. M. de Jong,Amanda C. M. Pronk,Sander Kooijman,Patrick C.N. Rensen,James E. Dahlman,Jeroen Eikenboom,Bart J.M. van Vlijmen	0
3	Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor 2024 ·Thrombosis Research ·(unknown),(unknown),Elisa Schrader Echeverri,(unknown),Richard Dirven,James E. Dahlman,Bart J.M. van Vlijmen,Cécile V. Denis,Jeroen Eikenboom	7
4	Small interfering RNA–mediated allele-selective silencing of von Willebrand factor in vitro and in vivo 2023 ·Blood Advances ·(unknown),Elisa Schrader Echeverri,Richard Dirven,Kalina Paunovska,(unknown),Annika de Jong,(unknown),(unknown),Bart J.M. van Vlijmen,James E. Dahlman,Jeroen Eikenboom	14
5	Assessment of breast cancer progression and metastasis during a hypercoagulable state induced by silencing of antithrombin in a xenograft mouse model 2022 ·Thrombosis Research ·Jeroen T. Buijs,(unknown),El Houari Laghmani,Marco Heestermans,Bart J.M. van Vlijmen,Henri H. Versteeg	3
6	Atherothrombosis model by silencing of protein C in APOE3-Leiden.CETP transgenic mice 2021 ·Journal of Thrombosis and Thrombolysis* ·(unknown),Jeroen Eikenboom,Marion J. Gijbels,Jimmy F.P. Berbée,Bart J.M. van Vlijmen	5
7	SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis 2020 ·Journal of Thrombosis and Haemostasis ·(unknown),Daniëlle M. Coenen,(unknown),Sophie Dólleman,Annemarie M. van Oeveren‐Rietdijk,(unknown),Hetty C. de Boer,Judith M.E.M. Cosemans,Henri H. Versteeg,Pierre‐Emmanuel Morange,Bart J.M. van Vlijmen,Chrissta X. Maracle,Grace M. Thomas	16
8	Ex vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA 2020 ·Thrombosis and Haemostasis ·Annika de Jong,Richard Dirven,Johan Boender,Ferdows Atiq,Seyed Yahya Anvar,Frank W.G. Leebeek,Bart J.M. van Vlijmen,Jeroen Eikenboom	22
9	Use of “C9/11 Mismatch” Control siRNA Reveals Sequence-Related Off-Target Effect on Coagulation of an siRNA Targeting Mouse Coagulation Factor XII 2019 ·Nucleic Acid Therapeutics ·Marco Heestermans,Annika de Jong,(unknown),Pieter H. Reitsma,Henri H. Versteeg,Henri M.H. Spronk,Bart J.M. van Vlijmen	2
10	Use of "C9/11 Mismatch" Control Small Interfering RNA Reveals Sequence-Related Off-Target Effect on Coagulation of an Small Interfering RNA Targeting Mouse Coagulation Factor XII 2019 ·Nucleic Acid Therapeutics ·Marco Heestermans,Annika de Jong,(unknown),Pieter H. Reitsma,(unknown),Henri M.H. Spronk,Bart J.M. van Vlijmen	1
11	Low human and murine Mcl-1 expression leads to a pro-apoptotic plaque phenotype enriched in giant-cells 2019 ·Scientific Reports ·(unknown),(unknown),Ilze Bot,Han Jin,Aimée J P M Franssen,Martine Bot,Saskia C.A. de Jager,Ivan Dzhagalov,You-Wen He,Bart J.M. van Vlijmen,Marion J. Gijbels,Chris Reutelingsperger,Theo J.C. van Berkel,Judith C. Sluimer,Lieve Temmerman,Erik A.L. Biessen	5
12	Correction of a dominant‐negative von Willebrand factor multimerization defect by small interfering RNA‐mediated allele‐specific inhibition of mutant von Willebrand factor 2018 ·Journal of Thrombosis and Haemostasis ·Annika de Jong,Richard Dirven,(unknown),(unknown),Bart J.M. van Vlijmen,Jeroen Eikenboom	19
13	The Immediate and Late Effects of Thyroid Hormone (Triiodothyronine) on Murine Coagulation Gene Transcription 2015 ·PLoS ONE ·Salam Salloum‐Asfar,Anita Boelen,Pieter H. Reitsma,Bart J.M. van Vlijmen	7
14	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice 2014 ·Clinical Cancer Research ·Seng Chuan Tang,Rolf W. Sparidans,(unknown),Tatsuki Fukami,Selvi Durmuş,Els Wagenaar,Tsuyoshi Yokoi,Bart J.M. van Vlijmen,Jos H. Beijnen,Alfred H. Schinkel	31
15	Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice 2009 ·Atherosclerosis ·Lianne S.M. Boesten,(unknown),(unknown),Lihui Hu,Amina F.A.S. Teunisse,Aart G. Jochemsen,Bastiaan Evers,Bob van de Water,Marion J. Gijbels,Bart J.M. van Vlijmen,Louis M. Havekes,Menno P.J. de Winther	27
16	Obesity promotes injury induced femoral artery thrombosis in mice 2008 ·Thrombosis Research ·Nobuo Nagai,Marc Hoylaerts,Audrey Cleuren,Bart J.M. van Vlijmen,H.R. Lijnen	24
17	Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death 2006 ·Cell Death and Differentiation ·Lianne S.M. Boesten,(unknown),Sarah De Clercq,Sarah Francoz,(unknown),Erik A.L. Biessen,Franz Hofmann,Susanne Feil,Robert Feil,Aart G. Jochemsen,C. Zurcher,Louis M. Havekes,Bart J.M. van Vlijmen,Jean‐Christophe Marine	55
18	The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis 2004 ·Journal of Lipid Research ·Jeltje R. Goudriaan,(unknown),Peter J. Voshol,Bas Teusink,Ko Willems van Dijk,Bart J.M. van Vlijmen,Johannes A. Romijn,Louis M. Havekes,Patrick C.N. Rensen	74
19	Clearance of coagulation factor VIII in very low‐density lipoprotein receptor knockout mice 2004 ·British Journal of Haematology ·Niels Bovenschen,Ko Willems van Dijk,Louis M. Havekes,Koen Mertens,Bart J.M. van Vlijmen	18
20	Use of transgenic mice in lipoprotein metabolism and atherosclerosis research 1997 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Louis M. Havekes,Bart J.M. van Vlijmen,M.C.M. de Jong,Ko Willems van Dijk,(unknown)	9

About Bart J.M. van Vlijmen

Bart J.M. van Vlijmen is a scholar working on Hematology, Internal Medicine and Genetics, having authored 70 papers that have together received 2.1k indexed citations. Recurring topics across this work include Blood Coagulation and Thrombosis Mechanisms (18 papers), Lipoproteins and Cardiovascular Health (10 papers) and Platelet Disorders and Treatments (10 papers). The work is most often cited by research in Hematology (515 citations), Internal Medicine (98 citations) and Immunology (482 citations). Bart J.M. van Vlijmen has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include Louis M. Havekes, Niels Bovenschen, Marten H. Hofker, Koen Mertens, Theo J.C. van Berkel, Lianne S.M. Boesten, Mark Kockx, Ko Willems van Dijk, Erik A.L. Biessen and J. Wouter Jukema. Their work appears in journals such as Journal of Biological Chemistry, Circulation and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact